The market is punishing Piramal Pharma. Is it an overreaction?

Despite recent stock corrections, Piramal Pharma has shown remarkable resilience, tripling investor wealth since 2023-24. However, concerns loom over global policy shifts and profit margins. Will this be an opportune moment for savvy investors? 

Markets